###### Abstract
Chemotherapy reduces cellular proliferation, a key requirement for tissue repair, while radiotherapy damages surrounding healthy tissues and impairs angiogenesis, leading to delayed wound healing [13]. Both treatments also increase the susceptibility to infections, which can further compromise the regenerative process [14]. The combined impact of these factors underscores the need for specialized strategies to enhance tissue repair and regeneration in these vulnerable populations. Recent innovations in GTR membrane technologies offer promising solutions to the challenges faced by immunocompromised patients. Bioactive membranes, which are engineered to release therapeutic agents such as growth factors, have shown the ability to enhance cellular proliferation, differentiation, and angiogenesis--key processes essential for effective tissue repair [15]. For example, membranes incorporating bone morphogenetic protein-2 (BMP-2) or vascular endothelial growth factor (VEGF) have demonstrated enhanced osteogenesis and vascularization in various preclinical studies [16]. Additionally, antibacterial membranes represent a critical advancement, addressing one of the most significant concerns in immunocompromised patients: the heightened risk of infection [17]. By incorporating antimicrobial agents such as silver nanoparticles or antibiotics, these membranes not only promote tissue regeneration but also provide a protective barrier against microbial colonization and biofilm formation [18]. Despite these advancements, there remains a significant gap in the literature regarding the use of GTR membranes in immunocompromised populations. Most studies to date have focused on healthy individuals or general populations, with limited investigation of how these technologies perform under the altered physiological conditions associated with immunocompromised patients. The few existing studies that address these populations often do so indirectly, using preclinical models or focusing on specific aspects of the regenerative process [19; 20]. As a result, there is a lack of comprehensive understanding regarding the efficacy, safety, and long-term outcomes of GTR membranes in these high-risk groups. Furthermore, the heterogeneity within immunocompromised populations, such as variations in glycemic control among diabetic patients or differences in cancer treatment regimens, adds another layer of complexity that is rarely addressed in current research. The need for a systematic evaluation of GTR membranes in immunocompromised patients is further emphasized by the growing prevalence of these patients worldwide [21]. According to the International Diabetes Federation, approximately 537 million adults were living with diabetes in 2021, a number expected to rise to 643 million by 2030 [22]. Similarly, global cancer incidence continues to increase, with an estimated 19.3 million new cases and nearly 10 million deaths reported in 2020 [23, 24]. These trends highlight the urgency of developing effective therapeutic strategies to manage the complications associated with these conditions, including impaired tissue regeneration. The integration of advanced GTR membranes into clinical practice for these populations holds the potential to significantly improve patient outcomes, reduce healthcare costs associated with chronic wounds, and enhance the quality of life for millions of patients [25]. This scoping review aims to address the critical gap in knowledge by providing a comprehensive review of the current evidence on the use of GTR membranes in immunocompromised patients. Furthermore, it seeks to identify key research gaps and proposes future directions to optimize GTR membrane strategies for these high-risk populations. The findings of this review can inform both clinical practice and future research, ultimately contributing to the development of targeted and effective regenerative therapies for immunocompromised individuals.